Alan Barkun, MD
Primary Axis:
Health Outcomes Research Focus:
Assessment of technologies in digestive diseases including bilio-pancreatic diseases, gastrointestinal bleeding, and Helicobacter pylori related gastrointestinal diseases.Endoscopic retrograde cholangio pancreatography, biliary obstruction, digestive endoscopy, technology evaluation, bilio-pancreatic diseases, upper gastrointestinal hemorrhage, peptic ulcer bleeding, meta-analyses, cost-effectiveness analyses
Email:
Email contact form Keywords:
Endoscopic retrograde cholangio pancreatography, biliary obstruction, digestive endoscopy, technology evaluation, bilio-pancreatic diseases, upper gastrointestinal hemorrhage, peptic ulcer bleeding, meta-analyses, cost-effectiveness analyses
Location:
Montreal General Hospital Publications:
Al-Sabah S, Barkun AN, Herba K, Adam V, Fallone C, Mayrand S, Pomier-Layrargues G, Kennedy W, Bardou M. Cost-effectiveness of proton-pump inhibition before endoscopy in upper gastrointestinal bleeding. Clin Gastroenterol Hepatol 6(4): 418-425; 2008.
Barkun AN, Bardou M, Marshall JK, the Non-variceal Upper GI Bleeding Consensus Conference Group. Consensus recommendations for managing patients with non-variceal upper gastrointestinal bleeding. Annals of Internal Medicine 139: 843-857; 2003.
Dial S, Delaney JAC, Barkun A, Suissa S. The use of gastric acid suppressive agents and the risk of community–acquired Clostridium difficile associated disease. JAMA 294(23): 2989-2995; 2005.
